Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-055610
Filing Date
2025-03-17
Accepted
2025-03-17 16:05:24
Documents
14
Period of Report
2025-05-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A d888198ddef14a.htm DEF 14A 537817
2 GRAPHIC g888198g01r16.jpg GRAPHIC 48190
3 GRAPHIC g888198g01x16.jpg GRAPHIC 50844
4 GRAPHIC g888198g01z16.jpg GRAPHIC 45969
5 GRAPHIC g888198g02x02.jpg GRAPHIC 30424
6 GRAPHIC g888198g03g03.jpg GRAPHIC 25533
7 GRAPHIC g888198g55g01.jpg GRAPHIC 71172
8 GRAPHIC g888198g55g02.jpg GRAPHIC 4138
9 GRAPHIC g888198g55g03.jpg GRAPHIC 3397
10 GRAPHIC g888198g55g04.jpg GRAPHIC 3757
11 GRAPHIC g888198g55g05.jpg GRAPHIC 3819
12 GRAPHIC g888198g55g55.jpg GRAPHIC 5323
13 GRAPHIC g888198g56g01.jpg GRAPHIC 1574
14 GRAPHIC g888198g56g02.jpg GRAPHIC 1829
  Complete submission text file 0001193125-25-055610.txt   948399
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39692 | Film No.: 25744389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)